The commercially available companion HRD test (MyChoice®) provided by Myriad Genetics was performed using the ovarian tumor tissue, revealing that homologous recombination repair was proficient in all the cases (genomic instability score was less than five in all the three cases, and neither the BRCA1 nor the BRCA2 pathogenic variant was present). The gene discussed is BRCA2; the disease is ovarian neoplasm.